A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency

Georgianne L. Arnold, Johan Van Hove, Debra Freedenberg, Arnold Strauss, Nicola Longo, Barbara Burton, Cheryl Garganta, Can Ficicioglu, Stephen Cederbaum, Cary Harding, Richard G. Boles, Dietrich Matern, Pranesh Chakraborty, Annette Feigenbaum

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Introduction: Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is a disorder of oxidation of long chain fat, and can present as cardiomyopathy or fasting intolerance in the first months to years of life, or as myopathy in later childhood to adulthood. Expanded newborn screening has identified a relatively high incidence of this disorder (1:31,500), but there is a dearth of evidence-based outcomes data to guide the development of clinical practice protocols. This consensus protocol is intended to assist clinicians in the diagnosis and management of screen-positive newborns for VLCAD deficiency until evidence-based guidelines are available. Method: The Oxford Centre for Evidence-based Medicine system was used to grade the literature review and create recommendations graded from A (evidence level of randomized clinical trials) to D (expert opinion). Delphi was used as the consensus tool. A panel of 14 experts (including clinicians, diagnostic laboratory directors and researchers) completed three rounds of survey questions and had a face-to-face meeting. Result: Panelists reviewed the initial evaluation of the screen-positive infant, diagnostic testing and management of diagnosed patients. Grade C and D consensus recommendations were made in each of these three areas. The panel did not reach consensus on all issues, particularly in the dietary management of asymptomatic infants diagnosed by newborn screening.

Original languageEnglish (US)
Pages (from-to)85-90
Number of pages6
JournalMolecular Genetics and Metabolism
Volume96
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Long-Chain Acyl-CoA Dehydrogenase
Practice Management
Clinical Protocols
Consensus
Screening
Newborn Infant
Neonatal Screening
Medicine
Evidence-Based Medicine
Expert Testimony
Muscular Diseases
Fats
Cardiomyopathies
Fasting
Oxidation
Randomized Controlled Trials
Research Personnel
Testing
Guidelines
VLCAD deficiency

Keywords

  • Clinical practice protocol
  • Delphi
  • Fatty acid oxidation
  • Newborn screening
  • Very long chain acyl-CoA dehydrogenase deficiency (VLCAD)

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Arnold, G. L., Van Hove, J., Freedenberg, D., Strauss, A., Longo, N., Burton, B., ... Feigenbaum, A. (2009). A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Molecular Genetics and Metabolism, 96(3), 85-90. https://doi.org/10.1016/j.ymgme.2008.09.008

A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. / Arnold, Georgianne L.; Van Hove, Johan; Freedenberg, Debra; Strauss, Arnold; Longo, Nicola; Burton, Barbara; Garganta, Cheryl; Ficicioglu, Can; Cederbaum, Stephen; Harding, Cary; Boles, Richard G.; Matern, Dietrich; Chakraborty, Pranesh; Feigenbaum, Annette.

In: Molecular Genetics and Metabolism, Vol. 96, No. 3, 03.2009, p. 85-90.

Research output: Contribution to journalArticle

Arnold, GL, Van Hove, J, Freedenberg, D, Strauss, A, Longo, N, Burton, B, Garganta, C, Ficicioglu, C, Cederbaum, S, Harding, C, Boles, RG, Matern, D, Chakraborty, P & Feigenbaum, A 2009, 'A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency', Molecular Genetics and Metabolism, vol. 96, no. 3, pp. 85-90. https://doi.org/10.1016/j.ymgme.2008.09.008
Arnold, Georgianne L. ; Van Hove, Johan ; Freedenberg, Debra ; Strauss, Arnold ; Longo, Nicola ; Burton, Barbara ; Garganta, Cheryl ; Ficicioglu, Can ; Cederbaum, Stephen ; Harding, Cary ; Boles, Richard G. ; Matern, Dietrich ; Chakraborty, Pranesh ; Feigenbaum, Annette. / A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. In: Molecular Genetics and Metabolism. 2009 ; Vol. 96, No. 3. pp. 85-90.
@article{40f835e1135a4e329f465f1742a96fc1,
title = "A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency",
abstract = "Introduction: Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is a disorder of oxidation of long chain fat, and can present as cardiomyopathy or fasting intolerance in the first months to years of life, or as myopathy in later childhood to adulthood. Expanded newborn screening has identified a relatively high incidence of this disorder (1:31,500), but there is a dearth of evidence-based outcomes data to guide the development of clinical practice protocols. This consensus protocol is intended to assist clinicians in the diagnosis and management of screen-positive newborns for VLCAD deficiency until evidence-based guidelines are available. Method: The Oxford Centre for Evidence-based Medicine system was used to grade the literature review and create recommendations graded from A (evidence level of randomized clinical trials) to D (expert opinion). Delphi was used as the consensus tool. A panel of 14 experts (including clinicians, diagnostic laboratory directors and researchers) completed three rounds of survey questions and had a face-to-face meeting. Result: Panelists reviewed the initial evaluation of the screen-positive infant, diagnostic testing and management of diagnosed patients. Grade C and D consensus recommendations were made in each of these three areas. The panel did not reach consensus on all issues, particularly in the dietary management of asymptomatic infants diagnosed by newborn screening.",
keywords = "Clinical practice protocol, Delphi, Fatty acid oxidation, Newborn screening, Very long chain acyl-CoA dehydrogenase deficiency (VLCAD)",
author = "Arnold, {Georgianne L.} and {Van Hove}, Johan and Debra Freedenberg and Arnold Strauss and Nicola Longo and Barbara Burton and Cheryl Garganta and Can Ficicioglu and Stephen Cederbaum and Cary Harding and Boles, {Richard G.} and Dietrich Matern and Pranesh Chakraborty and Annette Feigenbaum",
year = "2009",
month = "3",
doi = "10.1016/j.ymgme.2008.09.008",
language = "English (US)",
volume = "96",
pages = "85--90",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency

AU - Arnold, Georgianne L.

AU - Van Hove, Johan

AU - Freedenberg, Debra

AU - Strauss, Arnold

AU - Longo, Nicola

AU - Burton, Barbara

AU - Garganta, Cheryl

AU - Ficicioglu, Can

AU - Cederbaum, Stephen

AU - Harding, Cary

AU - Boles, Richard G.

AU - Matern, Dietrich

AU - Chakraborty, Pranesh

AU - Feigenbaum, Annette

PY - 2009/3

Y1 - 2009/3

N2 - Introduction: Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is a disorder of oxidation of long chain fat, and can present as cardiomyopathy or fasting intolerance in the first months to years of life, or as myopathy in later childhood to adulthood. Expanded newborn screening has identified a relatively high incidence of this disorder (1:31,500), but there is a dearth of evidence-based outcomes data to guide the development of clinical practice protocols. This consensus protocol is intended to assist clinicians in the diagnosis and management of screen-positive newborns for VLCAD deficiency until evidence-based guidelines are available. Method: The Oxford Centre for Evidence-based Medicine system was used to grade the literature review and create recommendations graded from A (evidence level of randomized clinical trials) to D (expert opinion). Delphi was used as the consensus tool. A panel of 14 experts (including clinicians, diagnostic laboratory directors and researchers) completed three rounds of survey questions and had a face-to-face meeting. Result: Panelists reviewed the initial evaluation of the screen-positive infant, diagnostic testing and management of diagnosed patients. Grade C and D consensus recommendations were made in each of these three areas. The panel did not reach consensus on all issues, particularly in the dietary management of asymptomatic infants diagnosed by newborn screening.

AB - Introduction: Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is a disorder of oxidation of long chain fat, and can present as cardiomyopathy or fasting intolerance in the first months to years of life, or as myopathy in later childhood to adulthood. Expanded newborn screening has identified a relatively high incidence of this disorder (1:31,500), but there is a dearth of evidence-based outcomes data to guide the development of clinical practice protocols. This consensus protocol is intended to assist clinicians in the diagnosis and management of screen-positive newborns for VLCAD deficiency until evidence-based guidelines are available. Method: The Oxford Centre for Evidence-based Medicine system was used to grade the literature review and create recommendations graded from A (evidence level of randomized clinical trials) to D (expert opinion). Delphi was used as the consensus tool. A panel of 14 experts (including clinicians, diagnostic laboratory directors and researchers) completed three rounds of survey questions and had a face-to-face meeting. Result: Panelists reviewed the initial evaluation of the screen-positive infant, diagnostic testing and management of diagnosed patients. Grade C and D consensus recommendations were made in each of these three areas. The panel did not reach consensus on all issues, particularly in the dietary management of asymptomatic infants diagnosed by newborn screening.

KW - Clinical practice protocol

KW - Delphi

KW - Fatty acid oxidation

KW - Newborn screening

KW - Very long chain acyl-CoA dehydrogenase deficiency (VLCAD)

UR - http://www.scopus.com/inward/record.url?scp=60649111860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60649111860&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2008.09.008

DO - 10.1016/j.ymgme.2008.09.008

M3 - Article

VL - 96

SP - 85

EP - 90

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 3

ER -